Summary Series (2021/03)
This study demonstrates the reproducibility of MMDx and the lack of significant disagreement between MMDx sign outs.
Summary Series (2021/03)
These two cases describe how MMDx was used to aid the management of two patients with Banff diagnoses of “borderline” and “Banff 1a TCMR.”
Summary Series (2021/03)
This study highlights the over simplification of the diagnosis of ABMR leading to a group of patients with less good outcomes being reclassified as ‘no ABMR’. The Molecular Microscope® Diagnostic System (MMDx) may resolve these issues by providing a clear molecular interpretation of the phenotype of rejection and extent of injury.
White Paper (2021/02)
We must consider, therefore, that a COVID-19 infection, as well as any future COVID-19 vaccine, may trigger changes in HLA antibody profiles. This, in turn, may have a profound effect on patients’ eligibility for transplant and risk of rejection after transplant.
Summary Series (2021/02)
Tissue-level molecular analysis of heart transplant biopsies with MMDx correlates with ISHLT grade of AMR but identifies important discrepancies. MMDx is a tool for personalized, precision diagnostics and is useful for designing and testing novel therapeutic interventions.
Summary Series (2021/01)
Defining patient advocacy and engagement for modern transplant and living donation care, particularly in light of the COVID-19 pandemic.
Summary Series (2021/01)
This study used serial dilution analysis to determine the point at which cPRA could be reduced below 98%, a value previously shown to significantly increase probability of transplant.
Transplant Patient Stories
Each quarter we have transplant patient or donor families share their incredible stories with us.
Join Our Mailing List
Want to be informed about product updates and upcoming workshops?
Or, enroll via text message:
Text HLANEWS to 22828 to get started.
(•▿•)> ⇣ Scroll down to see more Tweets.